Malignant pleural mesothelioma (MPM) is a very aggressive tumor with no known curative treatment. Better knowledge of the molecular mechanisms of mesothelial carcinogenesis is required to develop new therapeutic strategies. MPM, like all cancer cells, needs to maintain telomere length to prevent senescence. Previous studies suggested that the telomere lengthening mechanism in MPM is based mainly on telomerase activity. For this reason, we focused on the key catalytic enzyme, TERT (telomerase reverse transcriptase), by analyzing its gene expression in MPM and by studying the mechanism underlying its upregulation. We used our large collection of MPM composed of 61 MPM in culture and 71 frozen MPM tumor samples. Evaluation of TERT mRNA expression by quantitative RT-PCR showed overexpression in MPM in culture compared with normal mesothelial cells, and in MPM tumor samples compared with normal pleura. We identified a 'hot spot' of mutations in the TERT gene core promoter in both MPM in culture and in MPM tumor samples with an overall frequency of 15%. Furthermore, data clearly identified mutation in the TERT promoter as a mechanism of TERT mRNA upregulation in MPM. In contrast, gene copy number amplification was not associated with TERT overexpression. Then, we analyzed the clinicopathological, etiological and genetic characteristics of MPM with mutations in the TERT promoter. TERT promoter mutations were more frequent in MPM with sarcomatoid histologic subtype (Po0.01), and they were frequently associated with CDKN2A gene inactivation (P ¼ 0.03). In conclusion, a subgroup of MPM presents TERT promoter mutations, which lead to TERT mRNA upregulation. This is the first recurrent gain-of-function oncogenic mutations identified in MPM.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive tumor arising in the pleural cavities. The major risk factor for MPM is past exposure to asbestos, a mineral fiber known as a carcinogenic xenobiotic, which induces genomic and genetic alterations. 1 Other risk factors include exposure to non-asbestos fibers such as erionite, the effect of ionizing radiations, contamination by the Simian virus, SV40 and genetic factors such as germline mutations in the BAP1 gene encoding a nuclear deubiquitinase. 2, 3 MPM is resistant to conventional anticancer therapies (surgery, radiotherapy and chemotherapy). Its aggressiveness and the lack of curative treatment are responsible for the poor prognosis associated with MPM. There is a strong need to increase our knowledge about the molecular alterations in MPM to develop new therapies.
Molecular aspects of mesothelial carcinogenesis include chromosomal abnormalities, gene mutations, epigenetic alterations, gene expression changes and, more generally, signal pathway dysregulation. 4 Concerning genetic alterations, mainly recurrent somatic mutations in tumor suppressor genes have been reported in MPM. The most frequently inactivated genes in MPM are CDKN2A and CDKN2B, which reside at the same locus on chromosome 9 in 9p21 and encode cell cycle regulatory proteins, NF2, which encodes a multifunctional protein linking cytoskeletal components with proteins in the cell membrane, and BAP1. 4, 5 Knowledge of gene mutations provides insight into specific signal pathways that are altered in MPM, opening the way for future therapeutic strategies based on molecular characteristics of tumors such as targeted therapies.
One of the hallmarks of cancer is the immortalization of the tumor cells that need to counteract telomeres that shorten at each round of DNA replication. In normal cells, in the absence of a lengthening mechanism, telomeres become too short and tumor cell senescence occurs. The main telomere maintenance mechanism involves an enzyme complex, the telomerase, which synthesizes de novo telomeres. Another mechanism based on homologous recombination, the alternative lengthening of telomeres, has been described for maintaining telomere length. 6 However, while alternative lengthening of telomere mechanism was identified in 18% of peritoneal mesothelioma (44 cases), 7 it was not found in an equivalent series of MPM (43 cases). 8 Telomerase activity was detected between 91 and 100% of MPM, 1 depending on the study. 8, 9 These results suggest that maintenance of telomere length in MPM relies mainly on telomerase activity and, consequently, on the expression of the key catalytic enzyme, TERT (telomerase reverse transcriptase). So far, only one study has analyzed TERT expression in MPM using formalin-fixed tumors by immunohistochemistry (68 cases) and in situ hybridization (46 cases), and detected TERT expression in 99% of MPM, but mechanisms of TERT upregulation are unknown. 10 In this study, we evaluated TERT gene expression at the mRNA level in a large series of MPM, as a good correlation between telomerase activity and the level of TERT mRNA is generally observed in human cells. 11 The recent evidence of mutations in the TERT promoter that may increase its transcription [12] [13] [14] led us to determine the frequency of these mutations in MPM and their possible contribution to TERT overexpression. Correlation between TERT gene mutation and clinicopathological, epidemiological and genetic characteristics of MPM was also examined.
RESULTS AND DISCUSSION
TERT expression in MPM TERT gene expression was evaluated using qRT-PCR in 61 MPM in culture established in the laboratory, as reported in the literature, 15, 16 and in 71 MPM frozen tumor samples obtained from the French mesobank network (biobanks of three French hospitals: CHU de Caen; CHRU de Lille; CHU de Nice) and the biobank collection of the Hô pital Europé en Georges Pompidou (HEGP) in Paris. All MPMs were diagnosed by the center for pathological diagnosis certification (MESOPATH French National group) that is responsible for MPM diagnosis certification in France. 17 As controls, normal mesothelial cells cultures (five cases) were established after scraping the visceral pleura from surgical resection of blebs from patients with spontaneous pneumothorax. Normal pleura (17 cases) were obtained after stripping and dissecting the parietal pleura from patients with lung cancer, mediastinal lymphoma, pulmonary emphysema or spontaneous pneumothorax. Figure 1 shows significant higher expression of TERT mRNA in MPM in culture compared with normal mesothelial cells in culture (Figure 1a) , and in MPM tumor samples compared with normal pleura (Figure 1b) . In our series, 84% of MPM in culture and 85% of MPM tumor samples showed at least a twofold increase in TERT gene expression compared with their respective controls. Our data are in agreement with the upregulation of TERT protein in formalin-fixed MPM tumors, as previously described by immunohistochemistry in comparison to benign mesothelial lesions, 10 and demonstrate that TERT is overexpressed in MPM tumor cells at the transcriptional level.
Mutations in the TERT promoter A recent study identified highly recurrent TERT promoter somatic mutations in human melanoma at two 'hot spot' sites: g.1 295 228 and g.1 295 250, referred to as C228T and C250T, respectively ( Figure 2) . 12, 13 These somatic mutations were shown not to be restricted to melanoma and to be present in several types of tumors.
14 Transfection reporter gene assay in three human cell lines suggested that these mutations increase TERT promoter activity and may be involved in mRNA upregulation. 13 Data concerning TERT mutation in MPM are very limited at this time. No mutation was found in four MPM tumor samples. 14 The TERT promoter was also studied in two MPM cell lines and mutation was found in the H2052 cell line. 13 To clarify the presence or not of TERT promoter mutations in MPM, we performed DNA sequence analysis of the TERT promoter using our MPM sample collection. We identified TERT promoter mutations in 15.2% of MPM samples (20/132 cases), that is, 19.7% of MPM in culture (12/61 cases) and 11.3% of MPM tumor samples (8/71 cases) ( Figure 2 ). The lower TERT promoter mutation rate in MPM tumor samples than in MPM in culture could be related to decreased sensitivity to detect mutations in frozen tumors because of the presence of normal cells. Mutations were detected only in the C228T 'hotspot' site, which is also the most frequently mutated in other cancers.
14 Sequence analysis showed that this mutation affected only one of the alleles of the TERT gene locus in MPM in culture. It is likely that this is a somatic mutation, as has been exclusively found in others tumors. [12] [13] [14] All mutations consist of a cytosine-to-thymine transition that generates a potential Ets/TCF binding site, as described previously. 12, 13 The presence of this transcription factor binding site could increase the TERT promoter activity and, consequently, TERT mRNA expression.
Role of TERT promoter mutation on gene expression The relationship between TERT promoter mutation and TERT gene expression was then studied. Analysis of qRT-PCR data showed significantly higher levels of mRNA expression in MPM with TERT . Briefly, single-stranded cDNA was synthesized from 1.5 mg of Trizol-prepared total RNA using random primers and the high-capacity cDNA reverse transcription kit (Life Technologies). Real-time quantitative PCR was performed using pre-defined TaqMan probe and primer sets for TERT (Hs00972656_m1; Life Technologies) in an ABI PRISM 7900HT System. Expression of TERT gene was normalized to internal control ribosomal 18S relative to the mean expression of the corresponding gene in normal mesothelial cells in culture, according to the DDCt method. Histograms are the mean±s.e.m. P-values determined by the Mann-Whitney test using GraphPad prism software (version 5.0b) are indicated above each data set. Data show significant upregulation of the TERT gene in MPM compared with normal mesothelial cells and tissues.
promoter mutation in both MPM in culture (Figure 3a) and MPM tumor samples (Figure 3b) . Our results clearly identified genetic alterations of the TERT promoter as a mechanism of TERT mRNA upregulation in MPM. However, it seems that mutation in the TERT promoter is not the only mechanism involved in TERT overexpression, as several MPM without TERT promoter mutation showed a higher level of expression than normal tissue. It was suggested that upregulation of TERT in cancer cells could result from an increase of the gene copy number. 18 The 5p chromosomal region, which encompasses the TERT gene locus, is a recurrent region of chromosomal alterations in MPM. Gain of this region is reported in 22 to 55% of MPM in recent studies using genomic high-throughput analyses. 4 In our collection of MPM in culture, the 5p15.3 region is gained in 49.5% of MPM (16/33 cases). 16 Mutations in the TERT promoter and gain of the 5p15.3 region are not mutually exclusive since three mutated MPM showed a gain in the 5p15.3 region, whereas four mutated MPM showed no chromosomal alteration. Analysis of MPM without mutation in the TERT promoter showed no significant mRNA expression changes between MPM with or without gain in the 5p15.3 region (Supplementary Figure S1) . Our results suggest that chromosomal amplification of the TERT gene is not involved in the upregulation of TERT in MPM. A transcriptional mechanism could be responsible for TERT upregulation in MPM without mutation in its promoter, as TERT gene expression is regulated by several transcription factors or oncogenes, which may be dysregulated in MPM. 11, 19 For example, MPM expresses c-Myc, a transcriptional activator of TERT. 20 Epigenetic mechanisms, which regulated the expression of several genes in MPM, could also be involved in TERT expression regulation, as it was shown in others tumor cell types. 4, 19 Several mechanisms are involved in TERT upregulation in MPM, but it should be underlined that MPM with TERT promoter mutation have the highest gene expression of TERT.
Clinicopathological, etiological and genetic characteristics of MPM with mutation in the TERT promoter The main clinicopathological characteristics and epidemiologic data of our MPM collection are summarized in Supplementary  Table S1 . An association between mutation in the TERT promoter and histologic subtypes of MPM was observed. Histologic types were defined by the MESOPATH French National group, responsible for MPM diagnosis certification in France. 17 Three main histologic subtypes are described for MPM: epithelioid, sarcomatoid and biphasic. Several unusual morphological variants have also been identified, including desmoplastic MPM, which are a sarcomatoid MPM with a predominance of dense collagenous stroma. The sarcomatoid subtypes have the worse prognostic compared with other histologic subtypes, and desmoplastic MPM (6/15 cases, 40.0%) showed a significantly higher frequency of mutation in the TERT promoter than epithelioid MPM (10/95 cases, 10.5%) ( Table 1) . Biphasic MPM, which consists of a combined epithelioid and sarcomatoid pattern, showed an intermediate rate of mutation (3/16 cases, 18.8%). A difference in the mutation rate between histologic subtypes was also observed for glioma, and the authors suggested that tumors with high frequencies (X15%) of TERT promoter mutations arose in tissues with relatively low rates of self-renewal.
14 However, a low renewal rate of normal mesothelial cells in the pleura has been reported. 21 One might suggest that MPM subtypes arise from mesothelial cells with Figure 2 . TERT promoter mutation. Mutations in the TERT promoter were screened by Sanger sequencing in 61 MPM in culture and 71 MPM tumor samples. Briefly, the promoter region was amplified from genomic DNA by PCR, and fluorescent-based automated cycle sequencing was performed by the BigDye Terminator method (Life Technologies) using a multicapillary sequencer (ABI 3130 Genetic Analyzer). Mutations were detected using Sequencher software (Gene Codes Corp., Ann Arbor, MI, USA) and verified by independent amplification and sequencing. Schematic representation of the TERT promoter is annotated with the localizations of the TERT transcription (TSS) and translation (ATG) start sites, the regions targeted by the specific primers used for the PCR amplification and sequencing (in green), and the two 'hotspot' mutations (in red): g.1 295 228 and g.1 295 250, referred to as C228T and C250T, respectively. 13 At the top, nucleotide numbering indicates the position on chromosome 5 in the GRCh37 assembly, and at the bottom, it is related to the TERT translation start site. Mutations were only found at the C228T 'hotspot' site in 15% of MPM. Representative sequence chromatograms of wild-type MPM and mutated MPM with cytosineto-thymine transition are shown. The sequence and the chromatograms are represented on the minus strand of genomic DNA. On the right, the number of MPM with mutation at the C228T 'hotspot' site is given in MPM in culture and tumor samples. different dividing properties with regard to their in situ heterogeneity and different capabilities in mesothelium regeneration. 22 No significant association was found between mutation in the TERT promoter and the other clinicopathological characteristics of MPM (Supplementary Table S1 ). A trend can be observed in the epidemiological data. The evaluation of asbestos exposure in MPM patients was based on clinical reports or by intervieweradministered questionnaires. MPM patients were then broken down into three classes by an occupational hygienist based on the probability of exposure: ascertained, probable/possible and null. Higher frequency of mutation is observed in MPM of patients with ascertained asbestos exposure (15/75 cases, 20.0%) than in MPM of patients with probable/possible exposure (2/17 cases, 11.8%) or null exposure (2/29 cases, 6.9%), but these differences were not significant (P ¼ 0.23). A greater population would be needed to determine the relevance of these findings. The action mechanism of asbestos might facilitate escape from senescence in MPM. Asbestos is a well-known mutagen whose action mechanism involves oxidative stress and impairment of mitosis progression. Oxidative stress damages DNA and downregulates the expression of TERT mRNA. 23 Prolonged mitosis was found to produce DNA damage at telomeres. 24 TERT overexpression related to mutation in the TERT promoter could counteract the downregulation and impact on telomere maintenance.
Genetic alterations in genes involved in mesothelial carcinogenesis (CDKN2A, CDKN2B, BAP1, NF2) and in more common cancer-related genes (TP53) were previously identified in our cell bank composed of 61 MPM in culture (published 16, [25] [26] [27] and unpublished data). The genetic alteration profile of MPM in culture with TERT promoter mutation is shown in Supplementary Figure  S2 and Supplementary Table S2 . TERT promoter mutations are found only in MPM with CDKN2A alteration. In comparison to the MPM without TERT promoter mutation, a significantly higher frequency of alterations in CDKN2A gene is observed in MPM with TERT promoter mutation (P ¼ 0.03) ( Table 1) . Genetic alterations in NF2 and CDKN2B, which is the same locus as CDKN2A, are also more frequent than in MPM with no mutation in the TERT promoter. At the opposite, fewer mutations are found in BAP1 gene, but these differences are not significant (Table 1) . To analyze CDKN2A mutation on MPM tumor samples, we performed multiplex ligation-dependent probe amplification for the 9p21 locus on 69/71 MPM tumor samples, as CDKN2A genetic alterations consisted mainly in exon deletions in MPM in culture (98% of overall mutation at the CDKN2A locus). The multiplex ligation-dependent probe amplification was carried out using SALSA ME024 kits (MRC-Holland, Amsterdam, The Netherlands) and peak height ratios lower than 0.7 were considered as indicative of deletion. The association between the alterations at the TERT promoter and CDKN2A gene was also observed in MPM tumor samples. Among the eight MPM tumor samples mutated in TERT promoter, six showed exon deletion in the CDKN2A gene (Supplementary Table S2 ). By taking into account MPM in culture and MPM tumor samples, the genetic alterations in CDKN2A gene were more frequent in MPM with TERT promoter mutation (P ¼ 0.01). Data mining of the Horn et al.,
12 study also showed a higher frequency of CDKN2A alteration in melanoma with (57.3%) than without (31.4%) TERT promoter mutations (Po0.01). CDKN2A has a role in the regulation of senescence. 28 Association of upregulation of TERT by mutation and CDKN2A loss by inactivating mutation may reinforce an increase in the lifespan of MPM cells and their escape from senescence, one hallmark of neoplastic progression. 29 It was also shown that P16/INK4A, one of the proteins encoded by the CDKN2A gene, repressed TERT expression at the transcriptional level in breast normal and cancer cells. 30 It would be interesting to determine whether TERT promoter mutations still induce TERT overexpression in the presence of P16/INK4A in MPM.
The main finding of this study is the identification of TERT promoter mutation in MPM, which accounts for TERT overexpression. Interestingly, this mutation is associated with the MPM histologic phenotype and to genetic alterations in the CDKN2A tumor suppressor gene. To our knowledge, this is the first 'hotspot' oncogenic mutation identified in MPM. Only recurrent inactivating mutations in tumor suppressor genes have been identified in MPM as of this time. 4 Identification of recurrent oncogenic mutation has a great impact on our knowledge of mesothelial carcinogenesis. Fisher's exact test determined using GraphPad prism software (version 5.0b).
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